- 01
- 04
Our Focused Therapeutic Areas
We focus on the development of small-molecule drugs
for Immune & inflammatory disease, fibrosis and
cancer with unmet medical needs.
Our own artificial intelligence
drug discovery platform, DeepZema®
DeepZema® enables the best lead optimization and R&D productivity.
Our Latest News
- All
- News
- Notice
2026-06-22[News]
Innovo Therapeutics Receives MFDS Approval for Phase 3 Clinical Trial of Scar Treatment INV-001 in South Korea
News Provided by Innovo TherapeuticsJune 22, 2026, 09:00 AM KST· Phase 2 study demonstrated a statistically significant 24.5% reduction in scar formation versu
2026-05-14[News]
[대웅제약] '팔방미인' 15-PGDH 억제제, 적응증 확장 기대
[프레스나인] 금감소증·관절·섬유화 등 글로벌 연구 활발, 후속 확장 여지 충분 ☞ 기사 원문 보기
2026-05-13[News]
Innovo Therapeutics and Daewoong Pharmaceutical Enter into Licensing Agreement for INV-008, an Investigational Oral Therapy for Inflammatory Bowel Disease
News Provided by Innovo Therapeutics Inc.May 13, 2026, 08:30 AM KST · Advancing Global Development of INV-008: A First-in-Class Oral 15-PGDH Inhibitor f
2026-05-13[News]
이노보테라퓨틱스, 대웅제약에 6,625억 원 규모 염증성장질환 신약 기술이전
[이데일리] 선급금 65억 원, 제 3자 기술이전 시 수익 분배 별도 ☞ 기사 원문 보기
2026-06-22[News]
Innovo Therapeutics Receives MFDS Approval for Phase 3 Clinical Trial of Scar Treatment INV-001 in South Korea
News Provided by Innovo TherapeuticsJune 22, 2026, 09:00 AM KST· Phase 2 study demonstrated a statistically significant 24.5% reduction in scar formation versu
2026-05-14[News]
[대웅제약] '팔방미인' 15-PGDH 억제제, 적응증 확장 기대
[프레스나인] 금감소증·관절·섬유화 등 글로벌 연구 활발, 후속 확장 여지 충분 ☞ 기사 원문 보기
2026-05-13[News]
Innovo Therapeutics and Daewoong Pharmaceutical Enter into Licensing Agreement for INV-008, an Investigational Oral Therapy for Inflammatory Bowel Disease
News Provided by Innovo Therapeutics Inc.May 13, 2026, 08:30 AM KST · Advancing Global Development of INV-008: A First-in-Class Oral 15-PGDH Inhibitor f
2026-05-13[News]
이노보테라퓨틱스, 대웅제약에 6,625억 원 규모 염증성장질환 신약 기술이전
[이데일리] 선급금 65억 원, 제 3자 기술이전 시 수익 분배 별도 ☞ 기사 원문 보기